Travere Therapeutics (TVTX) Net Income towards Common Stockholders (2016 - 2024)
Historic Net Income towards Common Stockholders for Travere Therapeutics (TVTX) over the last 16 years, with Q4 2024 value amounting to $4000.0.
- Travere Therapeutics' Net Income towards Common Stockholders rose 10025.36% to $4000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $4000.0, marking a year-over-year increase of 10015.77%. This contributed to the annual value of -$915000.0 for FY2024, which is 10034.54% down from last year.
- According to the latest figures from Q4 2024, Travere Therapeutics' Net Income towards Common Stockholders is $4000.0, which was up 10025.36% from -$100000.0 recorded in Q3 2024.
- In the past 5 years, Travere Therapeutics' Net Income towards Common Stockholders ranged from a high of $240.0 million in Q3 2023 and a low of -$121.6 million during Q4 2020
- Over the past 5 years, Travere Therapeutics' median Net Income towards Common Stockholders value was -$101500.0 (recorded in 2024), while the average stood at -$3.5 million.
- Per our database at Business Quant, Travere Therapeutics' Net Income towards Common Stockholders crashed by 657439.9% in 2021 and then skyrocketed by 156569.03% in 2023.
- Travere Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$121.6 million in 2020, then rose by 27.01% to -$88.8 million in 2021, then surged by 122.32% to $19.8 million in 2022, then plummeted by 107.96% to -$1.6 million in 2023, then surged by 100.25% to $4000.0 in 2024.
- Its last three reported values are $4000.0 in Q4 2024, -$100000.0 for Q3 2024, and -$757000.0 during Q2 2024.